Table IV.
Hazard Ratio and 95% Confidence Interval for Study Endpoints by Quartile of Plasmin-Antiplasmin (PAP) Complex, MESA, 2000–2006
PAP Quartiles | ||||
---|---|---|---|---|
Outcome Model |
≤3.446 nM | 3.447 – 4.418 nM |
4.419 – 5.654 nM |
>5.654 nM |
Total CVD | ||||
Events | 62 | 78 | 75 | 92 |
Person-years | 7379 | 7185 | 7206 | 7031 |
Crude | 1.00 (Reference) |
1.29 (0.93–1.81) |
1.25 (0.89–1.74) |
1.57 (1.14–2.17) |
Age, Sex and Race adjusted | 1.00 (Reference) |
1.05 (0.75–1.47) |
0.93 (0.66–1.31) |
0.95 (0.67–1.34) |
Age, Sex, Race and risk factor* adjusted | 1.00 (Reference) |
1.10 (0.78–1.55) |
1.10 (0.78–1.55) |
1.06 (0.74–1.51) |
Also adjusted for IL-6, Fibrinogen, and CRP | 1.00 (Reference) |
1.04 (0.74–1.46) |
0.92 (0.64–1.32) |
0.83 (0.56–1.22) |
Hard CHD | ||||
Events | 42 | 44 | 52 | 69 |
Person-years | 7428 | 7269 | 7271 | 7071 |
Crude | 1.00 (Reference) |
1.08 (0.71–1.64) |
1.28 (0.85–1.92) |
1.76 (0.71–1.64) |
Age, Sex and Race adjusted | 1.00 (Reference) |
0.86 (0.56–1.31) |
0.93 (0.61–1.42) |
1.03 (0.68–1.56) |
Age, Sex, Race and risk factor* adjusted | 1.00 (Reference) |
0.88 (0.57–1.35) |
1.06 (0.69–1.62) |
1.10 (0.72–1.68) |
Also adjusted for IL-6, Fibrinogen, and CRP | 1.00 (Reference) |
0.84 (0.54–1.29) |
0.91 (0.59–1.42) |
0.89 (0.56–1.41) |
Total Mortality | ||||
Events | 24 | 50 | 52 | 84 |
Person-years | 7599 | 7508 | 7463 | 7364 |
Crude | 1.00 (Reference) |
2.12 (1.30–3.44) |
2.22 (1.37–3.60) |
3.66 (2.32–5.76) |
Age, Sex and Race adjusted | 1.00 (Reference) |
1.60 (0.98–2.62) |
1.47 (0.90–2.41) |
1.87 (1.16–3.03) |
Age, Sex, Race and risk factor* adjusted | 1.00 (Reference) |
1.70 (1.02 – 2.73) |
1.60 (0.97 – 2.63) |
2.00 (1.22–3.27) |
Also adjusted for IL-6, Fibrinogen, and CRP | 1.00 (Reference) |
1.55 (0.94–2.55) |
1.38 (0.83–2.30) |
1.55 (0.92–2.62) |
Body mass index, systolic blood pressure, antihypertensive medications, LDL and HDL cholesterol, statin use, usual alcohol intake, smoking status, cigarette pack-years, exercise, and glycemia status.